Information Provided By:
Fly News Breaks for January 26, 2020
Jan 26, 2020 | 19:59 EDT
Goldman Sachs analyst Salveen Richter upgraded Denali Therapeutics (DNLI) to Buy from Neutral with a price target of $37, up from $20. The analyst believes the Denali is evolving into a triple platform story with a small molecule portfolio targeting mutated genetic targets/pathways; a leverageable multi-modality blood brain barrier Transport Vehicle platform; and a potential next-generation viral vector gene therapy vertical. With positive updates from Ph1b DNL201 and Ph1 DNL151, Richter has increased confidence in the program and await initial Sanofi (SNY)-partnered Ph1b DNL747 biomarker data in Alzheimer disease and ALS in mid-2020.
News For DNLI;SNY From the Last 2 Days
There are no results for your query DNLI;SNY